PYRUKYND Sales Forecast and Market Size Analysis - 2034

Key Factors Driving PYRUKYND Growth

1. First-in-class oral PK activator with disease-modifying potential

• PYRUKYND is the first approved oral activator of pyruvate kinase (PKR) for pyruvate kinase (PK) deficiency, a rare hemolytic anemia.
• Mechanism improves ATP production in red blood cells, reducing hemolysis and anemia (validated in Phase III ACTIVATE studies published in peer-reviewed literature).

2. Established commercial base with steady early uptake

• FY2024 net sales: ~$36.5 million, up from ~$26.8M in 2023 (~36% YoY growth)
• Quarterly sales trend:
• Q1: $8.2M
• Q2: $8.6M
• Q3: $9.0M
• Q4: $10.7M

3. Significant label expansion into thalassemia (major growth driver)

• Positive Phase III ENERGIZE and ENERGIZE-T trials showed:
• Significant hemoglobin improvement
• Reduced transfusion burden
• Regulatory filings submitted in US, EU, and Middle East, with FDA decision expected (PDUFA: Sept 2025)

4. Pipeline expansion into sickle cell disease (SCD)

• Phase III RISE UP study fully enrolled (>200 patients) with topline data expected in 2025
• Potential commercial launch in 2026 (if successful)
• Entry into SCD (large global population) could:
• Dramatically increase addressable market
• Transform PYRUKYND into a franchise-level asset

5. Multi-indication franchise strategy (hemolytic anemias)

• Ongoing development across:
• PK deficiency (approved)
• Thalassemia (regulatory stage)
• SCD (Phase III)
• Pediatric PK deficiency and other indications

PYRUKYND Recent Developments

• In March 2026, Agios Pharmaceuticals announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has approved PYRUKYND (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. With this approval, PYRUKYND becomes the only medicine approved in the UAE for this patient population.
• In November 2025, Agios Pharmaceuticals announced topline results from the 52-week double-blind period of the global RISE UP Phase III trial of Mitapivat, an oral pyruvate kinase (PK) activator, in patients aged 16 years or older with sickle cell disease. RISE UP was designed with two primary endpoints and five key secondary endpoints to evaluate objective measures of hemolysis improvement as well as additional parameters of sickle cell disease. This comprehensive design enabled a broad assessment of the potential benefits of Mitapivat across multiple aspects of the disease.

“PYRUKYND Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of PYRUKYND for approved indication like Inborn error pyruvate metabolism disorders and Thalassaemia; as well as potential indication like Haemolytic anaemia, Sickle cell anaemia, and Diamond-Blackfan syndrome in the 7MM. A detailed picture of PYRUKYND’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the PYRUKYND for approved and potential indications. The PYRUKYND market report provides insights about PYRUKYND’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current PYRUKYND performance, future market assessments inclusive of the PYRUKYND market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of PYRUKYND sales forecasts, along with factors driving its market.

PYRUKYND Drug Summary

PYRUKYND (Mitapivat) is an oral, first-in-class small-molecule allosteric activator of the red blood cell pyruvate kinase (PKR) enzyme, developed by Agios Pharmaceuticals for the treatment of hemolytic anemias. It is approved for adults with Pyruvate Kinase Deficiency, a condition characterized by impaired ATP production in red blood cells leading to chronic hemolysis. By activating PKR, PYRUKYND enhances ATP generation and reduces levels of 2,3-diphosphoglycerate (2,3-DPG), thereby improving red blood cell survival and function while decreasing hemolysis. Clinical studies have demonstrated that the drug can significantly increase hemoglobin levels and reduce the need for transfusions in patients with PK deficiency. Administered orally, PYRUKYND represents a targeted, disease-modifying therapy and is also being investigated for additional indications such as Thalassemia and Sickle Cell Disease. The report provides PYRUKYND’s sales, growth barriers and drivers, post usage and approvals in multiple indications. 

Scope of the PYRUKYND Market Report

The report provides insights into:

• A comprehensive product overview including the PYRUKYND MoA, description, dosage and administration, research and development activities in approved indications like Inborn error pyruvate metabolism disorders and Thalassaemia; as well as potential indication like Haemolytic anaemia, Sickle cell anaemia, and Diamond-Blackfan syndrome.
• Elaborated details on PYRUKYND regulatory milestones and other development activities have been provided in PYRUKYND market report.
• The report also highlights PYRUKYND‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The PYRUKYND market report also covers the patents information, generic entry and impact on cost cut.
• The PYRUKYND market report contains current and forecasted PYRUKYND sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The PYRUKYND market report also features the SWOT analysis with analyst views for PYRUKYND in approved and potential indications.

Methodology

The PYRUKYND market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PYRUKYND Analytical Perspective

In-depth PYRUKYND Market Assessment

This PYRUKYND sales market forecast report provides a detailed market assessment of PYRUKYND for approved indication like Inborn error pyruvate metabolism disorders and Thalassaemia; as well as potential indication like Haemolytic anaemia, Sickle cell anaemia, and Diamond-Blackfan syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted PYRUKYND sales data uptil 2034.

PYRUKYND Clinical Assessment

The PYRUKYND market report provides the clinical trials information of PYRUKYND for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

PYRUKYND Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

PYRUKYND Market Potential & Revenue Forecast

• Projected market size for the PYRUKYND and its key indications
• Estimated PYRUKYND sales potential (PYRUKYND peak sales forecasts)
• PYRUKYND Pricing strategies and reimbursement landscape

PYRUKYND Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• PYRUKYND Market positioning compared to existing treatments
• PYRUKYND Strengths & weaknesses relative to competitors

PYRUKYND Regulatory & Commercial Milestones

• PYRUKYND Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

PYRUKYND Clinical Differentiation

• PYRUKYND Efficacy & safety advantages over existing drugs
• PYRUKYND Unique selling points  

PYRUKYND Market Report Highlights

• In the coming years, the PYRUKYND market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The PYRUKYND companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PYRUKYND’s dominance.
• Other emerging products for Inborn error pyruvate metabolism disorders and Thalassaemia; as well as potential indication like Haemolytic anaemia, Sickle cell anaemia, and Diamond-Blackfan syndrome are expected to give tough market competition to PYRUKYND and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PYRUKYND in approved and potential indications.
• Analyse PYRUKYND cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted PYRUKYND sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of PYRUKYND in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of PYRUKYND? How strong is PYRUKYND’s clinical and commercial performance?
• What is PYRUKYND’s clinical trial status in each individual indications such as Inborn error pyruvate metabolism disorders and Thalassaemia; as well as potential indication like Haemolytic anaemia, Sickle cell anaemia, and Diamond-Blackfan syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PYRUKYND Manufacturers?
• What are the key designations that have been granted to PYRUKYND for approved and potential indications? How are they going to impact PYRUKYND’s penetration in various geographies?
• What is the current and forecasted PYRUKYND market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of PYRUKYND in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to PYRUKYND for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is PYRUKYND? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.